- 专利标题： USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS
-
申请号： EP19164054.9申请日： 2015-08-08
-
公开(公告)号： EP3536323A1公开(公告)日： 2019-09-11
- 发明人: SHAMJI, Alykhan , SUNDBERG, Thomas , GRAY, Nathanael , XAVIER, Ramnik , SCHREIBER, Stuart L. , CHOI, Hwan Geun , LIANG, Yanke
- 申请人： Dana Farber Cancer Institute, Inc. , The Broad Institute , The General Hospital Corporation d/b/a Massachusetts General Hospital , President and Fellows of Harvard College
- 申请人地址： 450 Brookline Avenue Boston, Massachusetts 02215 US
- 专利权人： Dana Farber Cancer Institute, Inc.,The Broad Institute,The General Hospital Corporation d/b/a Massachusetts General Hospital,President and Fellows of Harvard College
- 当前专利权人： Dana Farber Cancer Institute, Inc.,The Broad Institute,The General Hospital Corporation d/b/a Massachusetts General Hospital,President and Fellows of Harvard College
- 当前专利权人地址： 450 Brookline Avenue Boston, Massachusetts 02215 US
- 代理机构： Barker, Kathrine Victoria
- 优先权： US201462035332P 20140808
- 主分类号： A61K31/519
- IPC分类号： A61K31/519 ; A61P1/00 ; A61P37/00
摘要：
The present disclosure provides methods of treating and/or preventing inflammatory bowel disease (IBD) and graft-versus-host disease (GVHD) using salt-inducible kinase (SIK) inhibitors, such as macrocyclic SIK inhibitors of Formula ( I ), imidazolyl SIK inhibitors of Formula ( II ), and urea and carbamate SIK inhibitors of Formula ( III-A ) ( e.g ., urea and carbamate SIK inhibitors of Formula ( III )).
信息查询
IPC分类:
